

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**中生北控生物科技股份有限公司**  
**BIOSINO BIO-TECHNOLOGY AND SCIENCE INCORPORATION**  
*(a joint stock limited company incorporated in the People's Republic of China with limited liability)*  
**(Stock Code: 8247)**

**PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION**

This announcement is made by Biosino Bio-Technology and Science Incorporation (the “**Company**”) pursuant to Rule 17.50(1) of the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited (the “**GEM Listing Rules**”).

On 1 January 2022, the GEM Listing Rules were amended by, among others, adopting a uniform set of 14 core standards for shareholder protections for issuers regardless of their place of incorporation set out in Appendix 3 to the GEM Listing Rules. Accordingly, the board (the “**Board**”) of directors (the “**Director(s)**”) of the Company proposes to make certain amendments to the existing articles of association of the Company (the “**Articles of Association**”) to conform with the said core standards for shareholder protections and to incorporate other consequential and housekeeping amendments (the “**Proposed Amendments**”).

The Proposed Amendments are subject to the approval of shareholders of the Company (the “**Shareholders**”) by way of a special resolution at the annual general meeting of the Company to be held on 25 May 2023 (the “**AGM**”). Notice of the AGM together with the proxy form and the reply slip were despatched to the Shareholders on 6 April 2023.

A circular containing, among other things, particulars relating to the Proposed Amendments to the Articles of Association will be despatched to the Shareholders in due course.

By order of the Board  
**Biosino Bio-Technology and Science Incorporation**  
**Tung Woon Cheung, Eric**  
*Company Secretary*

Beijing, the People's Republic of China, 28 April 2023

As at the date of this announcement, the Board comprises:

*Chairman and executive Director*

Mr. Wu Lebin (吳樂斌先生)

*Vice chairman and non-executive Director*

Dr. Sun Zhe (孫哲博士)

*Vice chairman and executive Director*

Mr. Lin Yanglin (林楊林先生)

*Non-executive Director*

Ms. Cheng Yali (程亞利女士)

*Independent non-executive Directors*

Dr. Zheng Yongtang (鄭永唐博士), Mr. Lu Qi (陸琪先生) and Prof. Shen Jiangan (沈劍剛教授)

*This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, (1) the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive; and (2) there are no other matters the omission of which would make any statement herein or this announcement misleading.*

*This announcement will remain on the “Latest Listed Company Information” page on the website of Hong Kong Exchanges and Clearing Limited at [www.hkexnews.hk](http://www.hkexnews.hk) for at least 7 days from the date of its posting and on the website of the Company at [www.zhongsheng.com.cn](http://www.zhongsheng.com.cn).*